Matthew Roach
About Matthew Roach
Matthew Roach is an Associate Director at BridgeBio in Raleigh, North Carolina, specializing in the development of production and purification processes for adeno-associated virus in gene therapy. He has a diverse background in biomanufacturing and has held various positions at notable companies including Pfizer and Precision BioSciences.
Work at BridgeBio
Matthew Roach has been serving as Associate Director at BridgeBio since 2022. He is based in Raleigh, North Carolina, where he focuses on the development of production and purification processes for adeno-associated virus (AAV) in gene therapy. His role involves overseeing projects that aim to enhance the efficiency and effectiveness of gene therapy applications.
Previous Experience in the Biotech Industry
Before joining BridgeBio, Matthew Roach held several positions in the biotechnology sector. He worked at Precision BioSciences, Inc. as a Process Development Engineer from 2019 to 2020, and later as Team Leader for AAV Process Development from 2021 to 2022. His experience also includes a tenure at Pfizer as a Senior Associate Scientist from 2018 to 2019 and as an Associate Scientist from 2017 to 2018.
Education and Expertise
Matthew Roach earned his Bachelor’s Degree in Biological Sciences from North Carolina State University, where he studied from 2012 to 2016. He furthered his education by obtaining a Master of Science in Microbiology and Cell Science from the University of Florida, completing his studies from 2018 to 2020. His academic background supports his specialization in biomanufacturing science, particularly in gene therapy applications.
Background in Research and Development
Matthew Roach has a solid foundation in research and development, having worked as an Undergraduate Researcher and Biomanufacturing Training Associate at North Carolina State University from 2015 to 2017. His early career included a summer internship in 2016, which contributed to his practical experience in the field. This background has equipped him with the skills necessary for his current role in gene therapy.